{"title":"S90 小儿萎缩性变性胃炎:IPEX综合征的一种罕见表现形式","authors":"Alicia Olave-Pichon, Nishaben Patel","doi":"10.14309/01.ajg.0000996104.82359.a7","DOIUrl":null,"url":null,"abstract":".Thiscaseseriespresented4patientswithCDwhoreceivedsirolimustherapyforaprimaryindicationofrefractoryCD.Allpatientshadfailedtreatmentwithatleast6otherIBD-therapies. Our results reveal 1 of 4 patients reporting symptomatic improvement and whilst treatment escalation was not required, imaging measures of in fl ammation remained equivocal. Furthermore, all 4 patients required sirolimus discontinuation due to adverse e ff ects. With minimal data currently available for use of sirolimus therapy in adults with refractory IBD, our fi ndings suggest that its role may be limited by treatment-derived adverse e ff ects. Further large-scale studies are needed to investigate the e ffi ciency of sirolimus therapy in refractory IBD, with particular attention to treatment-limiting adverse e ff ects.","PeriodicalId":188050,"journal":{"name":"The American Journal of Gastroenterology","volume":"596 ","pages":"S25 - S25"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"S90 Pediatric Atrophic Metaplastic Gastritis: A Rare Presentation of IPEX Syndrome\",\"authors\":\"Alicia Olave-Pichon, Nishaben Patel\",\"doi\":\"10.14309/01.ajg.0000996104.82359.a7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\".Thiscaseseriespresented4patientswithCDwhoreceivedsirolimustherapyforaprimaryindicationofrefractoryCD.Allpatientshadfailedtreatmentwithatleast6otherIBD-therapies. Our results reveal 1 of 4 patients reporting symptomatic improvement and whilst treatment escalation was not required, imaging measures of in fl ammation remained equivocal. Furthermore, all 4 patients required sirolimus discontinuation due to adverse e ff ects. With minimal data currently available for use of sirolimus therapy in adults with refractory IBD, our fi ndings suggest that its role may be limited by treatment-derived adverse e ff ects. Further large-scale studies are needed to investigate the e ffi ciency of sirolimus therapy in refractory IBD, with particular attention to treatment-limiting adverse e ff ects.\",\"PeriodicalId\":188050,\"journal\":{\"name\":\"The American Journal of Gastroenterology\",\"volume\":\"596 \",\"pages\":\"S25 - S25\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The American Journal of Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14309/01.ajg.0000996104.82359.a7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/01.ajg.0000996104.82359.a7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
S90 Pediatric Atrophic Metaplastic Gastritis: A Rare Presentation of IPEX Syndrome
.Thiscaseseriespresented4patientswithCDwhoreceivedsirolimustherapyforaprimaryindicationofrefractoryCD.Allpatientshadfailedtreatmentwithatleast6otherIBD-therapies. Our results reveal 1 of 4 patients reporting symptomatic improvement and whilst treatment escalation was not required, imaging measures of in fl ammation remained equivocal. Furthermore, all 4 patients required sirolimus discontinuation due to adverse e ff ects. With minimal data currently available for use of sirolimus therapy in adults with refractory IBD, our fi ndings suggest that its role may be limited by treatment-derived adverse e ff ects. Further large-scale studies are needed to investigate the e ffi ciency of sirolimus therapy in refractory IBD, with particular attention to treatment-limiting adverse e ff ects.